GW Pharmaceuticals (GWPH)

Business description

GW is a UK-based speciality pharma company developing cannabinoid medicines. Lead pipeline candidate Epidiolex is undergoing Phase III trials for childhood epilepsy. Sativex is marketed by partners in a number of EU countries for MS spasticity.

Stock data

Market cap.US$2738.5m
Last closeUS$108.65
High / Low (52 weeks)US$134.0 / US$94.1
Stock market listingUS
Forecast net cash (US$m)302.2
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual7.54.71.0
Relative *5.22.2(12.4)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Acarix Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Acucela
Addex Therapeutics Adherium
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris AFT Pharmaceuticals
Agennix Akari Therapeutics
Alchemia Alexza Pharmaceuticals
Algeta Alimera Sciences
ALK Abello Alkermes
Allergy Therapeutics Alliance Pharma
Allium Medical Solutions Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Angle Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Aratana Therapeutics Ardea Biosciences
Ardelyx Arena Pharmaceuticals
arGEN-X Argos Therapeutics
Ariad Pharmaceuticals Arix Bioscience
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Ascendis Pharma ASLAN Pharmaceuticals
Astex Pharmaceuticals Athersys
Atossa Genetics Avacta Group
Avalanche Biotechnologies AVEO Pharmaceuticals
Avita Medical Balda
Basilea Pharmaceutica Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences BioLineRx
BiondVax Pharmaceuticals Bionomics
Bionor Pharma Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio Bone Therapeutics
BrainStorm Cell Therapeutics BTG
C4X Discovery Holdings Can-Fite BioPharma
Capstone Therapeutics Carmat
Cell Therapy Celldex Therapeutics
Cellectis Cellular Biomedicine Group
Celyad Cerulean Pharma
Circadian Technologies Clal Biotechnology
Clavis Pharma Cleveland BioLabs
Clinigen Group Clinuvel
co.don AG Collplant Holdings
Consort Medical Corium International
Crescendo Crossject
CSL Curis
Cytori Therapeutics Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Delcath Systems
Deltex Medical Derma Sciences
DiaSorin Diaxonhit
e-Therapeutics Egalet Corporation
EKF Diagnostics Emergent BioSolutions
Endocyte Epigenomics
Erytech Pharma Esperion Therapeutics
Evotec Exact Sciences
Exelixis Factor Therapeutics
Formycon Forward Pharma
Fresenius SE & Co. KGaA Futura Medical
Galapagos Galmed Pharmaceuticals
Genedrive Genfit
Genkyotex Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
Halozyme Therapeutics Heat Biologics Inc.
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunicum Immunodiagnostic Systems Holdings
Immunovia ImmuPharma
Imprimis Pharmaceuticals Imugene
Incyte Corporation Infinity Pharmaceuticals
Innate Pharma Insmed
Intec Pharma International Stem Cell
Invion Ion Beam Applications
Ipsogen Iridex
Ironwood Pharmaceuticals Islet Sciences
Ixico KaloBios Pharmaceuticals
Karolinska Development Keryx Biopharmaceuticals
Kiadis Pharma Laboratorios Farmacéuticos ROVI
LCA-Vision LeMaitre Vascular
Lifeline Scientific LifeWatch
Ligand Pharmaceuticals Lipocine
Lombard Medical Technologies MagForce
Mast Therapeutics Medcom Tech
Medicago MediciNova
Medigene Medivir
Merrimack Pharmaceuticals Merrion Pharmaceuticals
Mesoblast MethylGene
MGC Pharmaceuticals Midatech Pharma
MISSION Therapeutics Molecular Partners
MolMed Mologen
Momenta Pharmaceuticals MorphoSys
Nanobiotix Nanosonics
Navidea Biopharmaceuticals Nektar Therapeutics
NeoStem Neovacs
NetScientific NeuroVive Pharmaceutical
Newron Pharmaceuticals Nexstim
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novacyt
Novogen NPS Pharmaceuticals
Nuevolution Ocata Therapeutics
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals Opexa Therapeutics
OPMEDIC Group Optos
Orexigen Therapeutics Orexo
Orgenesis Oryzon Genomics
Ossur OvaScience
Oxford BioMedica Pacific Edge
Paion Paladin Labs
Patheon PDL BioPharma
Pharmacyclics PharmaMar
Pharmaxis Pharming Group
Photocure Phylogica
Pixium Vision Pluristem Therapeutics
Prescient Therapeutics Prima BioMed
Probiodrug ProMetic Life Sciences
Prosensa Proteome Sciences
PsiOxus QRxPharma
Quantum Genomics Quantum Pharmaceuticals
Race Oncology RedHill Biopharma
Regeneus Relmada Therapeutics
ReNeuron Group Resverlogix
REVA Medical Rovi
RXi Pharmaceuticals Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Shire Sierra Oncology
Silence Therapeutics Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
SymBio Pharmaceuticals Synairgen
Synergy Health Synta Pharmaceuticals
Targovax TearLab Corp
Tekmira TESARO
Theraclion Therapix Biosciences
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Titan Pharmaceuticals
Tonix Pharmaceuticals Topotarget
Touchstone Innovations Transgene
Trillium Therapeutics Trimel Pharmaceuticals
TruScreen Ltd TxCell
UCB UDG Healthcare
uniQure NV Universal Biosensors
VBI Vaccines Vectura
Verastem Verisante Technology
Vernalis Verona Pharma
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus VolitionRx
WaferGen Biosystems Wilex
Xbrane Biopharma Xencor
Zafgen Zealand Pharma
Ziopharm Oncology

Company news

GW Pharmaceuticals to Present at Upcoming Investor Conferences

Tue, 05 Sep 2017 16:07:30 GMT

GW Pharmaceuticals Targets Long-Term Profits With Epidiolex

Wed, 06 Sep 2017 20:03:45 GMT

Investment Centers of America Inc. Takes Position in GW Pharmaceuticals PLC ...

Mon, 25 Sep 2017 14:26:15 GMT

GW Pharmaceuticals PLC (GWPRF) Climbs Higher Over Past 5 Sessions

Mon, 25 Sep 2017 12:45:00 GMT

GW Pharmaceuticals plc (NASDAQ:GWPH) Stock Sees The Needle Move 0.21%

Mon, 25 Sep 2017 21:33:45 GMT

Y/E Sep Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2015A 37.1 (70.9) (72.5) (274.14) N/A N/A
2016A 13.4 (109.1) (110.3) (345.47) N/A N/A
2017E 12.1 (166.8) (167.4) (568.42) N/A N/A
2018E 12.9 (161.6) (162.6) (551.07) N/A N/A

Last updated on 22/08/2017

Investment summary

GW Pharmaceuticals (GW) is developing an extensive cannabinoid portfolio with potential to treat a broad range of diseases. The lead pipeline asset is Epidiolex, now undergoing a multiple Phase III clinical study program for refractory childhood epilepsies. Initial top-line Phase III data from their one trial in Dravet syndrome and two trials in Lennox-Gastaut syndrome (LGS) were all statistically significant. A rolling NDA submission has commenced and is expected to be completed in October. A filing in the EU is expected in Q417. They have also commenced Phase III trials in Tuberous Sclerosis Complex (TSC) and infantile spasms (IS).

Last updated on 06/09/2017

Industry outlook

GW is the leading player in cannabinoid medicines. Cannabinoids are diverse chemical compounds that GW extracts from cannabis plant varieties (chemotypes) it has bred. Epidiolex has the potential to treat a broad range of treatment-refractory epilepsy conditions, while the portfolio extends to other orphan indications such as TSC epilepsy and NHIE.

Last updated on 06/09/2017

Key management

Geoffrey Guy, Chairman
Justin Gover, CEO
Adam David George, CFO

Company address

6th Floor
1 Cavendish Place
London
W1G 0QF
United Kingdom
+44 (0) 1980 557 000
View website